Pharming Group N.V. – NASDAQ:PHAR
Pharming Group N.V. stock price today
$12.71
+2.49
+24.36%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Pharming Group N.V. stock price monthly change
+16.67%
month
Pharming Group N.V. stock price quarterly change
+16.67%
quarter
Pharming Group N.V. stock price yearly change
-14.83%
year
Pharming Group N.V. key metrics
Market Cap | 6.20B |
Enterprise value | 788.60M |
P/E | 66.56 |
EV/Sales | 3.83 |
EV/EBITDA | 30.49 |
Price/Sales | 4.03 |
Price/Book | 4.05 |
PEG ratio | 48.26 |
EPS | -0.15 |
Revenue | 258.88M |
EBITDA | 12.09M |
Income | -10.35M |
Revenue Q/Q | 30.35% |
Revenue Y/Y | 28.44% |
Profit margin | 6.65% |
Oper. margin | 8.87% |
Gross margin | 91.46% |
EBIT margin | 8.87% |
EBITDA margin | 4.67% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePharming Group N.V. stock price history
Pharming Group N.V. stock forecast
Pharming Group N.V. financial statements
Average Price Target
$14
Potential upside: 10.14%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 54.89M | 1.31M | 2.4% |
|---|---|---|---|
| Sep 2023 | 66.66M | 3.46M | 5.2% |
| Dec 2023 | 81.86M | -2.72M | -3.33% |
| Mar 2024 | 55.45M | -12.41M | -22.39% |
| 2022-10-27 | 0.02 | 0.13 |
|---|---|---|
| 2023-03-16 | -0.19 | -0.19 |
| Jun 2023 | 429805000 | 229.43M | 53.38% |
|---|---|---|---|
| Sep 2023 | 436467000 | 226.52M | 51.9% |
| Dec 2023 | 470956000 | 252.17M | 53.55% |
| Mar 2024 | 441668000 | 235.72M | 53.37% |
| Jun 2023 | -9.62M | 20.30M | -2.62M |
|---|---|---|---|
| Sep 2023 | 3.52M | -145.57M | 5.24M |
| Dec 2023 | 12.18M | -3.90M | -1.02M |
| Mar 2024 | -9.68M | 662.43K | -438.96K |
Pharming Group N.V. alternative data
| Aug 2023 | 332 |
|---|---|
| Sep 2023 | 332 |
| Oct 2023 | 332 |
| Nov 2023 | 332 |
| Dec 2023 | 332 |
| Jan 2024 | 332 |
| Feb 2024 | 332 |
| Mar 2024 | 332 |
| Apr 2024 | 332 |
| May 2024 | 382 |
| Jun 2024 | 382 |
| Jul 2024 | 382 |
Pharming Group N.V. other data
0.00%
-0.00%
of PHAR is owned by hedge funds
23.34K
-6.16K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 12 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 27 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Sijmen de Vries M.B.A., M.D., MBA (1959) Pres, Chief Executive Officer & Executive Director | $1,180,000 |
Dr. Bruno M. L. Giannetti (1952) Consultant | $707,500 |
-
What's the price of Pharming Group N.V. stock today?
One share of Pharming Group N.V. stock can currently be purchased for approximately $12.71.
-
When is Pharming Group N.V.'s next earnings date?
Unfortunately, Pharming Group N.V.'s (PHAR) next earnings date is currently unknown.
-
Does Pharming Group N.V. pay dividends?
No, Pharming Group N.V. does not pay dividends.
-
How much money does Pharming Group N.V. make?
Pharming Group N.V. has a market capitalization of 6.20B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19.3% to 245.32M US dollars. Pharming Group N.V. made a loss 10.55M US dollars in net income (profit) last year or -$0.19 on an earnings per share basis.
-
What is Pharming Group N.V.'s stock symbol?
Pharming Group N.V. is traded on the NASDAQ under the ticker symbol "PHAR".
-
What is Pharming Group N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pharming Group N.V.?
Shares of Pharming Group N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pharming Group N.V.'s key executives?
Pharming Group N.V.'s management team includes the following people:
- Dr. Sijmen de Vries M.B.A., M.D., MBA Pres, Chief Executive Officer & Executive Director(age: 66, pay: $1,180,000)
- Dr. Bruno M. L. Giannetti Consultant(age: 73, pay: $707,500)
-
How many employees does Pharming Group N.V. have?
As Jul 2024, Pharming Group N.V. employs 382 workers, which is 15% more then previous quarter.
-
When Pharming Group N.V. went public?
Pharming Group N.V. is publicly traded company for more then 4 years since IPO on 23 Dec 2020.
-
What is Pharming Group N.V.'s official website?
The official website for Pharming Group N.V. is pharming.com.
-
How can i contact Pharming Group N.V.?
Pharming Group N.V. can be reached via phone at +31 71 524 7400.
-
What is Pharming Group N.V. stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Pharming Group N.V. in the last 12 months, the avarage price target is $14. The average price target represents a 10.14% change from the last price of $12.71.
Pharming Group N.V. company profile:
Pharming Group N.V.
pharming.comExchange:
NASDAQ
Full time employees:
382
Industry:
Biotechnology
Sector:
Healthcare
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Darwinweg 24
Leiden, 2333 CR
Leiden, 2333 CR
CIK: 0001828316
ISIN: US71716E1055
CUSIP: 71716E105
